Damora Therapeutics initiated the CLARITY-101 Phase 1/1b clinical trial for its drug DMR-001 targeting mutant CALR-driven blood disorders, receiving FDA clearance and expanding globally. The company reported $528.5 million in cash and securities, expected to fund operations into late 2029. New preclinical data will be presented at the ASH 2026 meeting, highlighting DMR-001's strong activity across CALR mutations. Upcoming milestones include clinical proof-of-concept data in mid-2027 and regulatory submissions for related drugs DMR-002 and DMR-003.
Damora Therapeutics' recent financial and clinical updates provide context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 05, 2026 04:11 WIB: out of 150 priced US health-sector stocks, 108 rose and 42 fell today. Notable movers include AHCO at USD 7.35 with a 1-day change of +17.04% and a typical hold time of 21 days, ACHC at USD 34.56 up +16.68% with a 9-day hold, and MRNA at USD 258.08 rising +12.97% with a 58-day hold time. Pluang order activity shows a majority selling trend for these stocks.
NOVAGOLD shareholders approved a transaction for New NOVAGOLD to acquire the remaining 40% interest in the Donlin Gold project from Paulson Advisers, increasing NOVAGOLD's ownership from 60% to 100%. This consolidation makes New NOVAGOLD the ultimate...
Fox Factory Holding Corp. has appointed Troy Henige as its new Chief Technology Officer (CTO) to lead the company's technology vision, strategy, and product roadmap. This new role aims to enhance innovation, connect engineering strengths across the c...
3M Company has reached a historic $7.35 billion settlement to resolve personal injury claims related to exposure to PFAS, toxic chemicals known as "forever chemicals." The settlement covers about 99% of existing claims, potentially benefiting 115,000...
The global e-learning market is projected to grow from $275.9 billion in 2026 to $506.6 billion by 2032, with a CAGR of 10.62% driven by rising internet connectivity, corporate upskilling demands, and government digital education initiatives. North A...
Royalty Pharma plc is the global leader in acquiring biopharmaceutical royalties, focusing on de-risked, post-proof-of-concept assets. The company offers investors exposure to blockbuster therapies with attractive risk-adjusted returns, including aro...
